All In Biotech

Drug Trial Radar · NCT00417937

A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily

A Multicenter, Double-Blind Clinical Trial to Assess the Efficacy and Tolerability of Topical Azelaic Acid 15% Gel Once Daily Compared to Topical Azelaic Acid 15% gelTwice Daily in Subjects With Papulopustular Rosacea

Last checked: Nov 20, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Jan 2007

Primary completion

Jun 2007

Study completion Jun 2007

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
Collaborators
Bayer
First posted
Jan 4, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy and tolerability of azelaic acid 15% gel applied once daily versus twice daily in the treatment of patients with papulopustular rosacea.

Conditions

  • Papulopustular Rosacea

Interventions

  • azelaic acid 15% gelDrug

    15% gel, topically applied once daily for six weeks

  • azelaic acid 15% gelDrug

    15% gel, topically applied twice daily for six weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator's global assessment scored on a seven point scaleTime frame: Measurements made during the course of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Intendis GmbH

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.